share_log

NeuroSense Therapeutics | EFFECT: Others

NeuroSense Therapeutics | EFFECT: Others

NeuroSense Therapeutics | EFFECT:其他
美股SEC公告 ·  2024/04/09 18:04

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on April 8, 2024. The notice, bearing the accession number 0001213900-24-030451, indicates that the company's submission, identified by the type POS AM and file number 333-260338, has been officially accepted by the SEC. This marks a significant regulatory milestone for NeuroSense Therapeutics, which is listed under the CIK number 0001875091.
NeuroSense Therapeutics has received a Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on April 8, 2024. The notice, bearing the accession number 0001213900-24-030451, indicates that the company's submission, identified by the type POS AM and file number 333-260338, has been officially accepted by the SEC. This marks a significant regulatory milestone for NeuroSense Therapeutics, which is listed under the CIK number 0001875091.
NeuroSense Therapeutics已於2024年4月8日收到美國證券交易委員會(SEC)的生效通知。該通知的註冊號爲0001213900-24-030451,表明該公司提交的文件已被美國證券交易委員會正式接受,其標識爲POS AM類型,文件號爲333-260338。這標誌着NeuroSense Therapeutics的一個重要的監管里程碑,該公司以CIK的編號爲0001875091上市。
NeuroSense Therapeutics已於2024年4月8日收到美國證券交易委員會(SEC)的生效通知。該通知的註冊號爲0001213900-24-030451,表明該公司提交的文件已被美國證券交易委員會正式接受,其標識爲POS AM類型,文件號爲333-260338。這標誌着NeuroSense Therapeutics的一個重要的監管里程碑,該公司以CIK的編號爲0001875091上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息